An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies

Matthew L. Cooper, Jaebok Choi, Karl Staser, Julie K. Ritchey, Jessica M. Devenport, Kayla Eckardt, Michael P. Rettig, Bing Wang, Linda G. Eissenberg, Armin Ghobadi, Leah N. Gehrs, Julie L. Prior, Samuel Achilefu, Christopher A. Miller, Catrina C. Fronick, Julie O’Neal, Feng Gao, David M. Weinstock, Alejandro Gutierrez, Robert S. FultonJohn F. DiPersio

Research output: Contribution to journalArticlepeer-review

264 Scopus citations


T cell malignancies represent a group of hematologic cancers with high rates of relapse and mortality in patients for whom no effective targeted therapies exist. The shared expression of target antigens between chimeric antigen receptor (CAR) T cells and malignant T cells has limited the development of CAR-T because of unintended CAR-T fratricide and an inability to harvest sufficient autologous T cells. Here, we describe a fratricide-resistant “off-the-shelf” CAR-T (or UCART7) that targets CD7+ T cell malignancies and, through CRISPR/Cas9 gene editing, lacks both CD7 and T cell receptor alpha chain (TRAC) expression. UCART7 demonstrates efficacy against human T cell acute lymphoblastic leukemia (T-ALL) cell lines and primary T-ALL in vitro and in vivo without the induction of xenogeneic GvHD. Fratricide-resistant, allo-tolerant “off-the-shelf” CAR-T represents a strategy for treatment of relapsed and refractory T-ALL and non-Hodgkin’s T cell lymphoma without a requirement for autologous T cells.

Original languageEnglish
Pages (from-to)1970-1983
Number of pages14
Issue number9
StatePublished - Sep 1 2018


Dive into the research topics of 'An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies'. Together they form a unique fingerprint.

Cite this